Program
TACI receptor-IgG Fc fragment fusion protein
Also written as “Atacicept”, “Atacicept 150 mg” and “Atacicept 75 mg”.
Its studies are mostly in Glomerulonephritis, IGA · Lupus Erythematosus, Systemic · Lupus Nephritis · Arthritis, Rheumatoid · Multiple Sclerosis, led by 2 companies.
Drug pageTACI receptor-IgG Fc fragment fusion protein: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germanyits history only | 130 open or running | phase 3since Dec 11, 2007 | Jan 30, 2007 | none ahead |
| Vera Therapeuticsits history only | 54 open or running | phase 3since Jan 11, 2021 | Jan 11, 2021 | Nov 2027phase 2 · NCT06983028 |
Also a collaborator on its studies: Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jan 30, 2007.
- Feb 15, 2008Phase 2 study in Optic NeuritisMerck KGaA, Darmstadt, Germany · NCT00624468 · 34 enrolled · United States, Australia, Belgium and more
- Feb 15, 2008Phase 3 study in Lupus Erythematosus, SystemicMerck KGaA, Darmstadt, Germany · NCT00624338 · 461 enrolled · United States, Argentina, Australia and more
- Mar 21, 2008Phase 2 study in Relapsing Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT00642902 · 255 enrolled · United States, Australia, Austria and more
- Apr 21, 2008Phase 2 study in Arthritis, RheumatoidMerck KGaA, Darmstadt, Germany · NCT00664521 · 27 enrolled · France, Netherlands, Sweden and more
- Feb 26, 2009Phase 2 study in Relapsing Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT00853762 · 74 enrolled · United States, Australia, Belgium and more
- Jun 7, 2011Phase 1 study in Lupus NephritisMerck KGaA, Darmstadt, Germany · NCT01369628 · 1 enrolled · United States
- Sep 22, 2011Phase 2 study in Lupus Erythematosus, SystemicMerck KGaA, Darmstadt, Germany · NCT01440231
- Oct 24, 2013Phase 2 study in Lupus Erythematosus, SystemicMerck KGaA, Darmstadt, Germany · NCT01972568 · 306 enrolled · United States, Argentina, Brazil and more
- Feb 21, 2014Phase 2 study in Lupus Erythematosus, SystemicMerck KGaA, Darmstadt, Germany · NCT02070978 · 253 enrolled · United States, Argentina, Brazil and more
- Jun 16, 2016Phase 2 study in Glomerulonephritis, IGAMerck KGaA, Darmstadt, Germany · NCT02808429 · 16 enrolled · United States, Japan, United Kingdom
- Jan 11, 2021Vera Therapeutics’ first study: phase 3 study in Glomerulonephritis, IGANew to Vera TherapeuticsVera Therapeutics · NCT04716231 · 428 enrolled · United States
- Nov 2, 2022Phase 3 study in Lupus NephritisVera Therapeutics · NCT05609812 · United States, Puerto Rico, Spain
- Oct 3, 2024Phase 2 study in Glomerulonephritis, IGAVera Therapeutics · NCT06674577 · 750 planned · United States
- May 13, 20252 phase 2 studiesVera Therapeutics · NCT07020923, NCT06983028
Ahead
- Nov 2027Primary completion: phase 2 study in Nephrotic SyndromeVera Therapeutics · NCT06983028
- May 21, 2031Primary completion: phase 2 study in Glomerulonephritis, IGAVera Therapeutics · NCT06674577
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07020923Glomerulonephritis, IGA · United States | 2 | Active, not recruiting | Vera Therapeutics | Sep 22, 2026 | 90 |
| NCT06983028Nephrotic Syndrome · United States | 2 | Recruiting | Vera Therapeutics | Nov 2027 | 250 |
| NCT06674577Glomerulonephritis, IGA · United States | 2 | By invitation | Vera Therapeutics | May 21, 2031 | 750 |
| NCT05609812Lupus Nephritis · United States, Puerto Rico, Spain | 3 | Withdrawn | Vera Therapeutics | Mar 15, 2026 | 0 |
| NCT04716231Glomerulonephritis, IGA · United States | 3 | Active, not recruiting | Vera Therapeutics | May 15, 2025 | 428 |
| NCT02808429Glomerulonephritis, IGA · United States, Japan, United Kingdom | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Feb 7, 2020 | 16 |
| NCT02070978Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Apr 5, 2016 | 253 |
| NCT01972568Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Apr 2016 | 306 |
| NCT01440231Lupus Erythematosus, Systemic | 2 | Withdrawn | Merck KGaA, Darmstadt, Germany | Aug 2013 | 0 |
| NCT01369628Lupus Nephritis · United States | 1 | Terminated | Merck KGaA, Darmstadt, Germany | Nov 2011 | 1 |
| NCT00853762Relapsing Multiple Sclerosis · United States, Australia, Belgium and more | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Sep 2009 | 74 |
| NCT00664521Arthritis, Rheumatoid · France, Netherlands, Sweden and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Oct 2010 | 27 |
| NCT00642902Relapsing Multiple Sclerosis · United States, Australia, Austria and more | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Sep 2009 | 255 |
| NCT00624468Optic Neuritis · United States, Australia, Belgium and more | 2 | Terminated | Merck KGaA, Darmstadt, Germany | Sep 2009 | 34 |
| NCT00624338Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Apr 2012 | 461 |
| NCT00595413Arthritis, Rheumatoid · United States, Germany | 2 | Completed | Merck KGaA, Darmstadt, Germany | Oct 2009 | 311 |
| NCT00573157Lupus Nephritis · United States, Czech Republic, Malaysia and more | 3 | Terminated | Merck KGaA, Darmstadt, Germany | Apr 2009 | 6 |
| NCT00430495Arthritis, Rheumatoid · United States, Canada | 2 | Completed | Merck KGaA, Darmstadt, Germany | Sep 2009 | 256 |
How it is read
Names in the registry
- “Atacicept”, 19 entries
- “Atacicept 150 mg”, 7 entries
- “Atacicept 75 mg”, 4 entries
- “Atacicept 25 mg”, 2 entries
- “Atacicept: with loading dose”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 4 studies
- Lupus Erythematosus, Systemic, 4 studies
- Lupus Nephritis, 3 studies
- Arthritis, Rheumatoid, 3 studies
- Multiple Sclerosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.